Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inecalcitol plus decitabine vs decitabine in older AML patients unfit for intensive chemotherapy
2015-002983-18Phase 2Terminated
- Sponsor
- Hybrigenics
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of inecalcitol in acute myeloid leukemia (AML) (2 arms), sponsored by Hybrigenics. Primary endpoint: overall survival. Started Mar 2017; status: terminated.
02
Drugs
inecalcitol
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2015-002983-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002983-18.